You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK):AK112單藥治療晚期非小細胞肺癌IB/II期臨牀研究結果在2022 ASCO年會發布
格隆匯 06-06 07:31

格隆匯6月6日丨康方生物-B(09926.HK)發佈公吿,公司自主研發的Ivonescimab( PD -1 / VEGF雙特異性抗體,研發代號:AK112)單藥治療晚期非小細胞肺癌(NSCLC)的Ib / II期研究結果在2022年美國臨牀腫瘤學會(ASCO)年會上發佈。

該研究是一項多中心及開放性臨牀試驗(臨牀試驗代碼NCT 04900363)。該研究主要研究終點為安全性和客觀緩解率(ORR),共分為10mg/kgQ3W,20mg/kgQ2W,20mg/kgQ3W或30mg/kgQ3W四個劑量水平。截至2022年3月4日,共入組96例患者,其中90例患者至少進行了一次治療後腫瘤評估。

目前,AK112單藥對比帕博利珠單抗單藥一線治療PD -L1表達陽性的NSCLC 的III 期臨牀研究正在開展中。AK112聯合化療對比化療在EGFR -TKI治療失敗的EGFR 突變的晚期非鱗NSCLC的III期臨牀研究(NCT 05184712)正在入組中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account